logo
Plus   Neg
Share
Email
Comment

Aeterna Zentaris' Phase3 Perifosine Trial Fails To Meet Primary Endpoint

Late-stage oncology drug development company Aeterna Zentaris Inc. (AEZS, AEZ.TO) said its Phase 3 trial evaluating perifosine in refractory advanced colorectal cancer patients failed to meet primary endpoint. Trading for Aeterna halted in early morning hours and shares are currently down more than 55 percent on the Nasdaq.

The focus of the X-PECT study was improvement of overall survival with perifosine in comparison with capecitabine + placebo. The trial involved 468 patients in 65 sites in the U.S and the study was conducted by the Company's North American licensee partner, Keryx Biopharmaceuticals, Inc. (KERX).

Aeterna Zentaris said it is very disappointed that the trial result. The company will continue further data analyses in collaboration with our licensee partners, in order to determine the future development strategy for perifosine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Inc. (WMT) reported fourth-quarter adjusted profit per share of $1.33 compared to $1.30, prior year. On average, 29 analysts polled by Thomson Reuters expected the company to report profit per share of $1.37 for the quarter. Analysts' estimates typically exclude special items. The company said... Shares of BHP Billiton plc were losing around 4 percent in the morning trading in London after the Anglo-Australian mining giant reported Tuesday sharply lower profit in its first half on US tax charge, despite higher revenues. Further, the company announced higher dividend, but trimmed its forecast for Group copper equivalent volume growth for fiscal 2018. Asia-focused lender HSBC Holdings Plc reported late Monday a significant growth in fiscal 2017 profit, reflecting higher revenues and the absence of loss related to Brazil operations. The company noted that all of its global businesses grew adjusted profits and three main global businesses generated improved adjusted revenue. Further, the company maintained its dividend.
comments powered by Disqus
Follow RTT